Edesa Biotech Inc. has announced positive results from a Phase 3 clinical trial evaluating its drug candidate paridiprubart (EB05) for the treatment of Acute Respiratory Distress Syndrome $(ARDS)$. The company reported that paridiprubart met both primary and secondary endpoints, demonstrating a statistically significant and clinically meaningful reduction in mortality at 28 and 60 days compared to placebo. Additionally, patients receiving paridiprubart showed a higher relative rate of clinical improvement, defined as no longer requiring invasive mechanical ventilation or organ support at Day 28. The trial enrolled adult patients from 38 hospitals in the USA, Canada, and Colombia. Safety data from over 275 subjects indicated that paridiprubart was generally well-tolerated. These results have already been presented by the company. Paridiprubart is also being evaluated in the U.S. government's "Just Breathe" study and receives development funding from the Government of Canada's Strategic Innovation Fund.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edesa Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-006690), on October 28, 2025, and is solely responsible for the information contained therein.
Comments